Laidlaw downgraded MEI Pharma to Hold from Buy without a price target after the company’s board determined to begin evaluation of strategic alternatives, including potential transactions as well as an orderly wind down of its operation. Given the uncertainty of the company’s future, including a possible total shut down, the firm downgraded the shares.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MEIP: